In Vitro Activities of Sitafloxacin (DU-6859a) and Six Other Fluoroquinolones Against 8,796 Clinical Bacterial Isolates

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2000 Mar 18

PMID 10722524

Citations 28

Authors

D Milatovic

F J Schmitz

S Brisse

J Verhoef

A C Fluit

Affiliations

Soon will be listed here.

Abstract

The in vitro activities of sitafloxacin, ciprofloxacin, trovafloxacin, levofloxacin, clinafloxacin, gatifloxacin, and moxifloxacin against 5,046 gram-negative bacteria, 3,344 gram-positive cocci, and 406 anaerobes were determined. Sitafloxacin was the most active agent against gram-positive cocci and anaerobes. Against Enterobacteriaceae and nonfermenters, its activity was either equivalent to or better than that of clinafloxacin.

Citing Articles

Recent Biochemical Advances in Antitubercular Drugs: Challenges and Future.

Jain A, Kumar R, Mothsra P, Sharma A, Singh A, Kumar Y Curr Top Med Chem. 2024; 24(21):1829-1855.

PMID: 38919089 DOI: 10.2174/0115680266286294240610102911.

The Medium Composition Impacts Biofilm Formation and Susceptibility to Antibiotics Applied in the Treatment of Bone Infections.

Paleczny J, Brozyna M, Dudek-Wicher R, Dydak K, Oleksy-Wawrzyniak M, Madziala M Int J Mol Sci. 2022; 23(19).

PMID: 36232864 PMC: 9569719. DOI: 10.3390/ijms231911564.

Therapeutic Potential of Sitafloxacin as a New Drug Candidate for Eradication in Korea: An In Vitro Culture-Based Study.

Choi Y, Lee S, Chung J, Kim K, Kwon K, Kim Y Antibiotics (Basel). 2021; 10(10).

PMID: 34680822 PMC: 8532961. DOI: 10.3390/antibiotics10101242.

The frontiers of addressing antibiotic resistance in Neisseria gonorrhoeae.

Rubin D, Ross J, Grad Y Transl Res. 2020; 220:122-137.

PMID: 32119845 PMC: 7293957. DOI: 10.1016/j.trsl.2020.02.002.

In vitro activity of five quinolones and analysis of the quinolone resistance-determining regions of gyrA, gyrB, parC, and parE in Ureaplasma parvum and Ureaplasma urealyticum clinical isolates from perinatal patients in Japan.

Kawai Y, Nakura Y, Wakimoto T, Nomiyama M, Tokuda T, Takayanagi T Antimicrob Agents Chemother. 2015; 59(4):2358-64.

PMID: 25645833 PMC: 4356753. DOI: 10.1128/AAC.04262-14.

References

Marshall S, Jones R . In vitro activity of DU-6859a, a new fluorocyclopropyl quinolone. Antimicrob Agents Chemother. 1993; 37(12):2747-53. PMC: 192801. DOI: 10.1128/AAC.37.12.2747. View

Fuchs P, Barry A, Brown S . In vitro activities of clinafloxacin against contemporary clinical bacterial isolates from 10 North American centers. Antimicrob Agents Chemother. 1998; 42(5):1274-7. PMC: 105802. DOI: 10.1128/AAC.42.5.1274. View

Wexler H, Molitoris E, Reeves D, Finegold S . In vitro activity of DU-6859a against anaerobic bacteria. Antimicrob Agents Chemother. 1994; 38(10):2504-9. PMC: 284775. DOI: 10.1128/AAC.38.10.2504. View

Nakashima M, Uematsu T, Kosuge K, Umemura K, Hakusui H, Tanaka M . Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers. Antimicrob Agents Chemother. 1995; 39(1):170-4. PMC: 162504. DOI: 10.1128/AAC.39.1.170. View

Cormican M, Marshall S, Jones R . Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin). Diagn Microbiol Infect Dis. 1995; 21(1):51-4. DOI: 10.1016/0732-8893(94)00116-e. View

Nakane T, Iyobe S, Sato K, Mitsuhashi S . In vitro antibacterial activity of DU-6859a, a new fluoroquinolone. Antimicrob Agents Chemother. 1995; 39(12):2822-6. PMC: 163041. DOI: 10.1128/AAC.39.12.2822. View

Visalli M, Jacobs M, Appelbaum P . MIC and time-kill study of activities of DU-6859a, ciprofloxacin, levofloxacin, sparfloxacin, cefotaxime, imipenem, and vancomycin against nine penicillin-susceptible and -resistant pneumococci. Antimicrob Agents Chemother. 1996; 40(2):362-6. PMC: 163117. DOI: 10.1128/AAC.40.2.362. View

Jones R, Johnson D, Biedenbach D, Marshall S . Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates. Diagn Microbiol Infect Dis. 1995; 23(3):123-7. DOI: 10.1016/0732-8893(95)00168-9. View

Hecht D, Wexler H . In vitro susceptibility of anaerobes to quinolones in the United States. Clin Infect Dis. 1996; 23 Suppl 1:S2-8. DOI: 10.1093/clinids/23.supplement_1.s2. View

10.

Nord C . In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Clin Infect Dis. 1996; 23 Suppl 1:S15-8. DOI: 10.1093/clinids/23.supplement_1.s15. View

11.

Kato N, Kato H, Watanabe K, Ueno K . Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria. Clin Infect Dis. 1996; 23 Suppl 1:S31-5. DOI: 10.1093/clinids/23.supplement_1.s31. View

12.

Korten V, Erdem I, Murray B . Bactericidal activity of the fluoroquinolone DU-6859a alone and in combination with other antimicrobial agents against multiresistant enterococci. Diagn Microbiol Infect Dis. 1996; 26(2):79-85. DOI: 10.1016/s0732-8893(96)00197-6. View

13.

Visalli M, Bajaksouzian S, Jacobs M, Appelbaum P . Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods. Antimicrob Agents Chemother. 1997; 41(7):1475-81. PMC: 163943. DOI: 10.1128/AAC.41.7.1475. View

14.

Cohen M, Huband M, Gage J, Yoder S, Roland G, Gracheck S . In-vitro activity of clinafloxacin, trovafloxacin, and ciprofloxacin. J Antimicrob Chemother. 1997; 40(2):205-11. DOI: 10.1093/jac/40.2.205. View

15.

Bauernfeind A . Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother. 1998; 40(5):639-51. DOI: 10.1093/jac/40.5.639. View

16.

Jones R, Barrett M, Biedenbach D . Interpretive criteria for susceptibility tests with DU-6859a and FK-037 tested against Haemophilus influenzae and Neisseria gonorrhoeae. Diagn Microbiol Infect Dis. 1994; 19(2):93-9. DOI: 10.1016/0732-8893(94)90119-8. View